



2800 Rockcreek Parkway
Kansas City, MO 64117
Direct: (816) 201-1024
Fax: (816) 474-1742

November 6, 2020
Page 1 of 2

Dear Sir or Madam,

Cerner Corporation, a leading supplier of electronic health record, clinical and revenue cycle information systems appreciate the opportunity to submit comments on certain of the provisions of the current standards approved by the National Coordinator during this open comment period in the Standards Version Advancement Process. We offer comments on the individual standards/implementation specifications outlined below.

Cerner Corporation hopes these comments will be of value to ONC in considering possible update to any of the current standards/implementation specifications. We are happy to help clarify any of the comments should ONC wish to pursue any such conversations with us during the period of public comment review.

Sincerely,

A handwritten signature in black ink, appearing to read 'John Travis', is written over a light blue horizontal line.

John Travis
Vice President and Regulatory Strategy Executive
Cerner Corporation



Page 2 of 2

**HL7 Implementation Guide for CDA® Release 2 - Level 3:
Healthcare Associated Infection Reports, Release 1 (U.S. Realm),
August 9, 2013**

§ 170.315(f)(6) - Transmission to public health agencies — antimicrobial use and resistance reporting

We note the availability of HL7 CDA® R2 Implementation Guide: Healthcare Associated Infection (HAI) Reports, Release 3 - US Realm – 2016. We recommend including this into the SVAP because NHSN is planning to move to requiring this new version of the standard for Antimicrobial Use and Resistance (AUR) reporting in the Summer of 2021.